Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.96, $1.13 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $53.16 million.

2021 Expense Guidance:

R&D spend in 2021, on a non-GAAP basis, is expected to be $26-$30 million, as compared to $27.8 million in 2020.

SG&A spend in 2021, on a non-GAAP basis, is expected to be $56-$60 million, as compared to $50.9 million in 2020.

The guidance provided in this section represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this press release.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.